Plain-English translation of NCT06783140 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial compares two different chemotherapy regimens for people with advanced pancreatic cancer that has a BRCA1, BRCA2, or PALB2 gene mutation and has stopped responding to initial treatment. One group will receive NABPLAGEM, a three-drug combination, while the other group receives a standard two-drug combination. The goal is to see which treatment works better for this specific group of patients.
Pancreatic cancer with these genetic mutations may respond differently to treatment than other pancreatic cancers. Researchers want to find out if adding a third drug () to the standard two-drug regimen can help patients live longer and control their cancer better.
You would be randomly assigned to receive either the three-drug combination or the standard two-drug combination. Both treatments are given intravenously on days 1 and 15 of each treatment cycle. You would have regular clinic visits for blood tests, scans, and monitoring for side effects. The study is small (targeting about 10 participants total) and is being conducted at the University Health Network in Toronto.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
Canada
Phase
Large-scale testing
Sponsor
University Health Network, Toronto
Enrollment target
~10 participants
Started
June 2025
Primary completion
June 2031
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2026.